N/A N=16 Surface Stimulation for Female Sexual Dysfunction
Female Sexual Dysfunction
Primary: 6 Weeks - Total FSFI Score — 26.0; 17.4 score on a scale — p=0.109
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=397 Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
Female Sexual Arousal Disorder · Hypoactive Sexual Desire Disorder
Primary: The Primary Efficacy Endpoint is Change From Baseline to End of Study in the Number of Satisfying Sexual Events (SSE) — 0.2; 0.6; 0.7; 0.8 SSEs — p=<0.05
Phase 3 N=949 Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
Sexual Dysfunctions, Psychological
Primary: Change From Baseline in the Number of Satisfying Sexual Events — 1.0; 0.6 sexual events
Phase 3 N=880 24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder
Sexual Dysfunctions, Psychological
Primary: Satisfying Sexual Event Monthly Change From Baseline at Final Visit — 0.8; 1.4; 1.6 number of events — p=0.0454
Phase 3 N=1,090 Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
Sexual Dysfunctions, Psychological
Primary: The Change From Baseline to Week 24 in the Score of the Female Sexual Function Index Desire Domain. — 1.0; 0.7 units on a scale
N/A N=79 Trial of Tibial Nerve Stimulation for Treating Sexual Dysfunction
Female Sexual Dysfunction
Primary: Female Sexual Function Index (FSFI) — 16.72; 16.88; 22.02; 21.22 score on a scale
Phase 1 N=24 Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Sexual Dysfunctions, Psychological
Primary: Flibanserin: Area Under the Curve; AUC_0-∞ — 2570 ng*h/mL
Phase 3 N=945 Flibanserin Versus Placebo in Premenopausal Women With HSDD
Sexual Dysfunctions, Psychological
Primary: Change From Baseline in the Frequency of Satisfying Sexual Events as Measured by the eDiary. — 1.2; 1.5; 0.9 events per month
Phase 3 N=1,385 6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA
Sexual Dysfunctions, Psychological
Primary: Mean Change From Baseline to 24 Weeks in the Frequency of Satisfying Sexual Events as Measured by the eDiary. — 1.5; 1.6; 1.6; 1.6 SSEs per week
Phase 3 N=1,584 Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
Sexual Dysfunctions, Psychological
Primary: Change From Baseline in the Frequency of Satisfying Sexual Events (SSE) as Recorded in the eDiary. — 1.4; 1.4; 1.9; 1.1 SSEs per 28 days
Phase 3 N=217 Effects of SH T00658ID on Libido
Contraception · Libido
Primary: Change From Baseline to Cycle 6 in the Total of Questions 1 to 6 of the Female Sexual Function Index (FSFI) - Full Analysis Set (FAS) — 6.45; 5.98 scores on a scale
Phase 4 N=40 Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder
Hypoactive Sexual Desire Disorder
Primary: Changes in Blood Oxygen Level Dependent (BOLD) Signal Change on Functional MRI — 9.98; 7.67 BOLD signal change
N/A N=47 Evaluation of Vitamin D in Women With PCOS and Sexual Dysfunction
Female Sexual Dysfunction · Polycystic Ovary Syndrome
Primary: Sexual Function — 24.8; 26.0 score on a scale — p=0.71
N/A N=61 A Mindfulness-based Intervention for Older Women With Low Sexual Desire
Hypoactive Sexual Desire Disorder · Sexual Dysfunction · Female Sexual Dysfunction
Primary: Feasibility - Number of Enrolled Women Participating in All Sessions — 15; 22 Participants — p=0.027
Phase 2 N=253 Efficacy and Safety of TBS-2 Testosterone Gel in Women With Acquired Female Orgasmic Disorder
Female Orgasmic Disorder
Primary: Number of Orgasms Over an 84 Day Period Compared to Placebo Over the Entire Treatment Period — 2.8; 3.9; 3.2; 1.9 orgasms
Phase 3 N=653 1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
Hypoactive Sexual Desire Disorder
Primary: Efficacy of a Fixed Dose of Bremelanotide as Measured by FSFI (Question Q1 and Q2), 28-day Recall. — 0.54; 0.24; 1.30; 0.77 score on a scale
Phase 3 N=480 Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder
Sexual Dysfunctions, Psychological
Primary: Frequency of Adverse Events — 331; 206; 58; 51 participants with any adverse event
Phase 3 N=614 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
Hypoactive Sexual Desire Disorder
Primary: Efficacy of a Fixed Dose of Bremelanotide as Measured by FSFI (Question Q1 and Q2), 28-day Recall. — 0.63; 0.21; 1.25; 0.70 score on a scale
N/A N=15 Effect of Peripheral Neuromodulation on Vaginal Blood Flow - Study 2
Female Sexual Dysfunction · Female Sexual Dysfunction Due to Physical Condition
Primary: Maximum Percent Change in Vaginal Pulse Amplitude (VPA) From the Average Baseline Value — 119.8; 94.3; 135.4; 113.5 percent change of VPA
N/A N=30 Women's Interventions for Sexual Health: WISH
Sexual Dysfunction, Physiological · Body Image · Libido; Loss, Aversion
Primary: Screen Failure Rate (a Measure of Feasibility) — 36 Participants
Phase 4 N=83 Effect of Antidepressants on Sex Hormone Levels and Sexual Functioning
Healthy
Primary: Change in 17-OH Pregnenolone — 120; 158; 171; 170 ng/dl — p=>0.8
N/A N=25 Comparative Effects of Nebivolol and Metoprolol on Female Sexual Function
Hypertension · Female Sexual Dysfunction
Primary: Change in Female Sexual Function Index — 1.24; 1.42 units on a scale
N/A N=148 Randomized Comparison of Mindfulness Versus Group Support for Treatment of Low Sexual Desire in Women
Low Female Sexual Desire
Primary: Female Sexual Distress Scale-Revised (FSDS-R) — 22.88; 25.68; 23.02; 23.87 units on a scale
N/A N=45 The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis
Multiple Sclerosis
Primary: Sexual Dysfunction (as Measured by the Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-19) ) — -0.697 units on a scale
Phase 3 N=447 Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction
Treatment Outcome
Primary: Change From Baseline in the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14) Total Score at Week 8 — 8.8; 6.6 scores on a scale — p=0.013
Early Phase 1 N=13 Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy
Breast Cancer · Vaginal Dryness · Dyspareunia
Primary: Total Female Sexual Function Index (FSFI) Score — 8.691; 18.783 units on a scale — p=<0.0005
Phase 3 N=136 Impact of Lactate-Containing Vaginal Lubricant on Sexual Dysfunction in Young Breast Cancer Survivors
Sexual Dysfunction · Breast Cancer Survivors
Primary: Change of Pain Score of Female Sexual Function Index — 1.15; 1.05 units on a scale
Phase 4 N=50 Treating Postmenopausal Dyspareunia Where it Hurts
Dyspareunia
Primary: Change in Median Dyspareunia Pain Scores After 4 Weeks Using Study Drug — -1.5; -3 score on a scale — p=0.08
N/A N=142 Sexual Function and Wellbeing in Females With Rectal Cancer
Rectal Cancer
Primary: Change in Serum Testosterone Levels Between Baseline and 1 Year After Surgery. — 0.6; 0.6; 0.6; 0.5 nmol/l — p=0.004
Phase 3 N=919 Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity
Atrophy · Vaginal Diseases
Primary: Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear (Dryness Strata) — -3.7; -31.7 percentage of parabasal cells